First Patient Dosed in STARSTRUCK Study
Telix today announces that the first patient has been dosed in a Phase I study of the Company’s investigational targeted radiation therapy, TLX250, in combination with a Merck KGaA, Darmstadt,…
Read moreNews & Views
Telix Quarterly Results and Investor Call / Webcast Notification
Telix today advises it will release its Appendix 4C Quarterly Cash Flow Report and Activities Report for the period ended 30 June 2023 on Wednesday 19 July 2023 at market…
Read more
New ZIRCON Phase III Data Presented at SNMMI: Potential Utility of TLX250-CDx in Staging and Monitoring ccRCC
today announces further details of the positive results from its completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (ClinicalTrials.gov Identifier:…
Read more
Telix Urology Innovation Showcase Webcast
Telix is pleased to provide a video recording of the Company’s briefing session for shareholders held on Wednesday, June 21, 2023, at The Yale Club in New York City….
Read more
Telix to Showcase ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline Developments at SNMMI
Telix today announces presentations from the Company’s investigational prostate (prostate specific-membrane antigen, or PSMA-targeting) and renal (carbonic anhydrase IX, or CAIX-targeting) diagnostic and therapeutic programs at the Society of Nuclear…
Read more
Telix to Expand Late-Stage Urologic Pipeline with Acquisition of Lightpoint Medical
Telix today announces it has entered into an agreement to acquire Lightpoint Medical and its SENSEI® radio-guided surgery business. Lightpoint Medical is a United Kingdom-based medical device company specialising in…
Read more
Telix Urology Innovation Showcase – June 21, 2023, at The Yale Club, New York City
Telix today provides an outline agenda for the Company’s briefing session for shareholders to be held on Wednesday, June 21, 2023, at The Yale Club in New York City, from…
Read more
First Patient Dosed in Phase II STARBURST Study of TLX250-CDx Exploring Indication Expansion
Telix today announces that the first patient has been dosed in a global Phase II study of the Company’s carbonic anhydrase- (CAIX)-targeting PET/CT[1] imaging agent TLX250-CDx (89Zr-DFO-girentuximab), exploring this potential…
Read more
Telix Recognised by the Australian Financial Review as Australia’s Highest Achieving Company for International Growth
News,
Telix has today been recognised as Australia’s highest achieving company for international growth in the Australian Financial Review’s Fast Global list. Fast Global celebrates Australian companies that are delivering real commercial…
Read more
Telix Opens European Radiopharmaceutical Production Facility
Telix today welcomes Willy Borsus, Vice-President of Wallonia, Minister of Economy, Research and Innovation, Digital, Agriculture, Urban Planning and Regional Planning to officially open Telix Manufacturing Solutions, the Company’s radiopharmaceutical production…
Read more